Summit Therapeutics Inc. (SMMT)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XMEX 
Is Summit Therapeutics a Millionaire Maker?
The potential upside of this stock is undeniably meaty.
Summit Therapeutics Stock: Sell or Hold Before Q3 Earnings?
Devoid of any marketed drug in its portfolio, investors will likely focus on SMMT's pipeline updates when it reports third-quarter results this month.
Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?
This drugmaker's lead candidate could become a top-selling cancer therapy.
Summit Stock Skyrockets Nearly 700% YTD: Time to Sell or Hold?
The rally in SMMT stock is driven by encouraging updates on its oncology candidate, which has the potential to become the next standard of care in the NSCLC space.
Billionaire Israel Englander Just Quietly Took a Stake in This Potentially Lucrative Pharmaceutical Stock. Should You?
Millennium Management just initiated a position in a small biotech company developing a new cancer drug.
Up 700% This Year, Is It Too Late to Invest in This Stock?
The shares have experienced a pullback in the past couple of weeks.
Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics
It's hard to go wrong with either company, but one is more appealing.
3 Things You Need to Know If You Buy Summit Therapeutics Stock Today
It's easier to invest confidently when you know both the pros and the cons in full.
2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts
The investment bank analysts who follow these stocks think they can soar even further, with some caveats.
Is Summit Therapeutics a Millionaire Maker?
This company's promising cancer drug could challenge Merck's $25 billion crown jewel.
Could Summit Therapeutics Become the Next Merck?
Recent developments are forcing comparisons between these two drugmakers.
Where Will Summit Therapeutics Be in 3 Years?
There's a lot riding on how its collaborator's studies end up performing.
